April 5, 2016
Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, is pleased to announce the appointment of Harold A. Deas, Jr. as Chief Executive Officer. Mr. Deas, who will retain his role as Chief Operating Officer, has been instrumental in helping Avion build a successful portfolio of Women’s Health and Dermatology products. Mr. Deas will be driving corporate expansion while identifying strategic opportunities within the markets core to the company’s business.
Daily commercial operations and management will continue to be led by Michael E. Sullivan, President of Avion. “Avion is fortunate to be able to foster the strong foundation of support and guidance we have benefitted from through Art’s leadership over the past 5 years,” stated Mr. Sullivan. “Art’s expertise will ensure Avion maintains a positive trajectory to fulfill our core business initiatives.”
“Avion has a bright future, and I am pleased to be part of the continued success,” said Mr. Deas. “We have identified a multitude of exciting opportunities to drive growth and are working furiously to help materialize these opportunities for execution as part of our daily product sales efforts.”
Avion Pharmaceuticals, LLC is a specialty pharmaceutical company formed to develop and market a portfolio of innovative pharmaceutical products in the Women’s Heath and Dermatology therapeutic areas. Avion Pharmaceuticals focuses on identifying opportunities to acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfill unmet medical needs. For additional information about Avion Pharmaceuticals please contact the company at 678-325-5188.